Literature DB >> 1664989

Control of viral disease: the development of Epstein-Barr virus vaccines.

A J Morgan1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1991        PMID： 1664989     DOI： 10.1007/bf00201472

Source DB:  PubMed          Journal:  Springer Semin Immunopathol        ISSN： 0344-4325


× No keyword cloud information.
  70 in total

1.  Vero cell-expressed Epstein-Barr virus (EBV) gp350/220 protects marmosets from EBV challenge.

Authors:  E A Emini; W A Schleif; M Silberklang; D Lehman; R W Ellis
Journal:  J Med Virol       Date:  1989-02       Impact factor: 2.327

2.  Comparison of EBV neutralization tests based on abortive infection or transformation of lymphoid cells and their relation to membrane reactive antibodies (anti-MA).

Authors:  A de Schryver; G Klein; J Hewetson; G Rocchi; W Henle; G Henle; D J Moss; J H Pope
Journal:  Int J Cancer       Date:  1974-03-15       Impact factor: 7.396

3.  Epstein-Barr virus-induced B-cell lymphoma after renal transplantation: acyclovir therapy and transition from polyclonal to monoclonal B-cell proliferation.

Authors:  D W Hanto; G Frizzera; K J Gajl-Peczalska; K Sakamoto; D T Purtilo; H H Balfour; R L Simmons; J S Najarian
Journal:  N Engl J Med       Date:  1982-04-15       Impact factor: 91.245

4.  Expression and secretion in yeast of a 400-kDa envelope glycoprotein derived from Epstein-Barr virus.

Authors:  L D Schultz; J Tanner; K J Hofmann; E A Emini; J H Condra; R E Jones; E Kieff; R W Ellis
Journal:  Gene       Date:  1987       Impact factor: 3.688

5.  Two major outer envelope glycoproteins of Epstein-Barr virus are encoded by the same gene.

Authors:  C Beisel; J Tanner; T Matsuo; D Thorley-Lawson; F Kezdy; E Kieff
Journal:  J Virol       Date:  1985-06       Impact factor: 5.103

6.  Antigenic analysis of the Epstein-Barr virus major membrane antigen (gp350/220) expressed in yeast and mammalian cells: implications for the development of a subunit vaccine.

Authors:  E A Emini; W A Schleif; M E Armstrong; M Silberklang; L D Schultz; D Lehman; R Z Maigetter; L F Qualtiere; G R Pearson; R W Ellis
Journal:  Virology       Date:  1988-10       Impact factor: 3.616

7.  Prevention of Epstein-Barr (EB) virus-induced lymphoma in cottontop tamarins by vaccination with the EB virus envelope glycoprotein gp340 incorporated into immune-stimulating complexes.

Authors:  A J Morgan; S Finerty; K Lovgren; F T Scullion; B Morein
Journal:  J Gen Virol       Date:  1988-08       Impact factor: 3.891

8.  Depletion of glycoprotein gp85 from virosomes made with Epstein-Barr virus proteins abolishes their ability to fuse with virus receptor-bearing cells.

Authors:  R S Haddad; L M Hutt-Fletcher
Journal:  J Virol       Date:  1989-12       Impact factor: 5.103

9.  Recombinant vaccinia virus expressing Epstein-Barr virus glycoprotein gp340 protects cottontop tamarins against EB virus-induced malignant lymphomas.

Authors:  A J Morgan; M Mackett; S Finerty; J R Arrand; F T Scullion; M A Epstein
Journal:  J Med Virol       Date:  1988-06       Impact factor: 2.327

10.  A structural investigation of the Epstein-Barr (EB) virus membrane antigen glycoprotein, gp340.

Authors:  A J Morgan; A R Smith; R N Barker; M A Epstein
Journal:  J Gen Virol       Date:  1984-02       Impact factor: 3.891
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.